Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunex' Leukine approved for allogeneic bone marrow transplantation; GM-CSF's fourth indication.

Executive Summary

IMMUNEX LEUKINE APPROVED FOR ALLOGENEIC BMT in HLA-matched related donors Nov. 24. Immunex' yeast-derived granulocyte-macrophage colony stimulating factor (sargramostim) was found to "shorten time to white blood cell count recovery, to decrease the length of hospital stay after the procedure and to reduce the overall incidence of infection," Immunex said Nov. 29.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel